BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer

Journal of the National Cancer Institute

Volumn 96, Issue 1, 2004, Pages 15-21

  Niell, Bethany L ^a   Rennert, Gad ^b,c   Bonner, Joseph D ^a   Almog, Ronit ^c   Tomsho, Lynn P ^a   Gruber, Stephen B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CARMEL MEDICAL CENTER   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOSINE; GUANINE; THYMINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FAMILY HISTORY; FEMALE; FOUNDER EFFECT; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; INTERVIEW; ISRAEL; JEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0842302522     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh008     Document Type: Article

References (25)

1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
2. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
3. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
4. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65.
5. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
6. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Study Consortium. JAMA 1997;277:915-9.
7. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med 1997;336:1401-8.
8. Drucker L, Stackievitz R, Shpitz B, Yarkoni S. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Res 2000;20:559-61.
9. Chen-Shtoyerman R, Figer A, Fidder HH, Rath P, Yeremin L, Bar Meir S, et al. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 2001;84:475-7.
10. Phipps RF, Perry PM. Familial breast cancer and the association with colonic carcinoma. Eur J Surg Oncol 1989; 15:109-11.
11. Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history. Genet Epidemiol 1993;10:235-44.
12. Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database [published erratum appears in J Natl Cancer Inst 1994;86:1802]. J Natl Cancer Inst 1994;86:1618-26.
13. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-14.
14. Gruber SB. Assay for detecting the I1307K susceptibility allele within the adenomatous polyposis coli gene. In: Killeen AA, editor. Methods in molecular medicine. Totowa (NJ): Humana Press; 2001. p. 263-70.
15. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol 1998; 148: 623-30.
16. Moslehi R, Chu W, Karlan B, Fishman D, Riscb H, Fields A, et al, BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-72.
17. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, et al. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 1998;20:62-5.
18. Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, et al. The APCI1307K allele and breast cancer risk. Nat Genet 1998; 20:13-4.
19. Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997;146:244-8.
20. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis 1985;38:289-93.
21. Seybolt LM, Vachon C, Potter K, Zheng W, Kushi LH, McGovern PG, et al. Evaluation of potential sources of bias in a genetic epidemiologic study of breast cancer. Genet Epidemiol 1997;14:85-95.
22. Madigan MP, Troisi R, Potischman N, Brogan D, Gammon MD, Malone KE, et al. Characteristics of respondents and non-respondents from a case-control study of breast cancer in younger women. Int J Epidemiol 2000;29:793-8.
23. Anderson DE. An inherited form of large bowel cancer: Muir's syndrome. Cancer 1980;45(5 Suppl): 1103-7.
24. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53.
25. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000;37:828-30.